174 related articles for article (PubMed ID: 36446043)
21. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death.
Ahrendsen JT; Sinai C; Meredith DM; Malinowski SW; Cooney TM; Bandopadhayay P; Ligon KL; Alexandrescu S
J Neuropathol Exp Neurol; 2021 Nov; 80(11):1052–1059. PubMed ID: 34580728
[TBL] [Abstract][Full Text] [Related]
22. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y;
Lancet Oncol; 2023 Aug; 24(8):925-935. PubMed ID: 37541273
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
24. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J
Clin Cancer Res; 2019 May; 25(9):2699-2707. PubMed ID: 30745300
[TBL] [Abstract][Full Text] [Related]
25. IDH-mutant gliomas with additional class-defining molecular events.
Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S
Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213
[TBL] [Abstract][Full Text] [Related]
26. Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.
Tyhonas JS; Arnold LD; Cox JM; Franovic A; Gardiner E; Grandinetti K; Kania R; Kanouni T; Lardy M; Li C; Martin ES; Miller N; Mohan A; Murphy EA; Perez M; Soroceanu L; Timple N; Uryu S; Womble S; Kaldor SW
J Med Chem; 2024 Feb; 67(3):1734-1746. PubMed ID: 38267212
[TBL] [Abstract][Full Text] [Related]
27. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.
Facchinetti F; Hollebecque A; Bahleda R; Loriot Y; Olaussen KA; Massard C; Friboulet L
Clin Cancer Res; 2020 Feb; 26(4):764-774. PubMed ID: 31585937
[TBL] [Abstract][Full Text] [Related]
28. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.
Chiba Y; Sudo K; Kojima Y; Okuma H; Kohsaka S; Machida R; Ichimura M; Anjo K; Kurishita K; Okita N; Nakamura K; Kinoshita I; Takahashi M; Matsubara J; Kusaba H; Yonemori K; Takahashi M
BMC Cancer; 2022 Aug; 22(1):869. PubMed ID: 35945547
[TBL] [Abstract][Full Text] [Related]
29. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.
Pathak P; Kumar A; Jha P; Purkait S; Faruq M; Suri A; Suri V; Sharma MC; Sarkar C
Brain Pathol; 2017 Sep; 27(5):580-589. PubMed ID: 27608415
[TBL] [Abstract][Full Text] [Related]
31. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
32. TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
Picca A; Di Stefano AL; Savatovsky J; Ducray F; Chinot O; Moyal EC; Augereau P; Le Rhun E; Schmitt Y; Rousseaux N; Yepnang AMM; Estellat C; Charbonneau F; Letourneur Q; Branger DF; Meyronet D; Fardeau C; Mokhtari K; Bielle F; Iavarone A; Sanson M
Neurooncol Adv; 2024; 6(1):vdae068. PubMed ID: 38813112
[TBL] [Abstract][Full Text] [Related]
33.
Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
[TBL] [Abstract][Full Text] [Related]
34. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
35. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
[TBL] [Abstract][Full Text] [Related]
36. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
37. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
38. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
39. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
40. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
Ramkissoon SH; Bandopadhayay P; Hwang J; Ramkissoon LA; Greenwald NF; Schumacher SE; O'Rourke R; Pinches N; Ho P; Malkin H; Sinai C; Filbin M; Plant A; Bi WL; Chang MS; Yang E; Wright KD; Manley PE; Ducar M; Alexandrescu S; Lidov H; Delalle I; Goumnerova LC; Church AJ; Janeway KA; Harris MH; MacConaill LE; Folkerth RD; Lindeman NI; Stiles CD; Kieran MW; Ligon AH; Santagata S; Dubuc AM; Chi SN; Beroukhim R; Ligon KL
Neuro Oncol; 2017 Jul; 19(7):986-996. PubMed ID: 28104717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
